iBio says it can meet NYSE listing requirements after equity falls below $6 million.

Reading Time: < 1 minute

blankiBio, Inc. received notice from the New York Stock Exchange that the Company fell  below certain of the exchange’s continued listing standards. The Newark-based  company is not in compliance with   the requirement of a listed company having stockholders’ equity of less than $6 million.

In a release, iBio said it believes it can provide a compliance plan by Dec. 21st. If not, the company  would be delisted from the exchange.

The Newark company develops vaccine systems that use plant technologies, robotics and other means. The approach reduces the costs and the amount of time required to manufacture vaccines. The company has struggled with a falling stock price, due to investor concerns about its earnings potential.

Facebook Comments